Connection

MICHAEL ITTMANN to Antineoplastic Agents

This is a "connection" page, showing publications MICHAEL ITTMANN has written about Antineoplastic Agents.
Connection Strength

0.199
  1. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
    View in: PubMed
    Score: 0.076
  2. Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. PLoS One. 2014; 9(9):e106289.
    View in: PubMed
    Score: 0.053
  3. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.036
  4. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004 Dec; 11(4):709-24.
    View in: PubMed
    Score: 0.027
  5. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 2006 Jan; 5(1):78-83.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.